Yescarta’s Median Time to CRS Improved by Prophylactic Corticosteroid Use; Thoughts on Frank Neumann Joining Kite as Worldwide Head of Clinical Development
On Wednesday, February 10, Gilead (Kite) announced (press release / abstract) updated results from cohort 6 of the Ph1/2 ZUMA-1 trial. The analysis showed that prophylactic use of corticosteroids has the potential to delay Yescarta’s CRS onset. Additionally, Gilead announced (press release) that Frank Neumann has joined Kite as Senior Vice President and Global Head of Clinical Development. Below, Celltelligence provides insights on how Yescarta’s improved safety profile could bring CRS onset parity with Breyanzi and if Kite’s recent senior management appointments could suggest a reprioritization towards solid tumors.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.